Ovarian Clear Cell Carcinoma Clinical Trial
Official title:
Sintilimab Plus Bevacizumab in Patients With Recurrent/Persistent Ovarian Clear Cell Carcinoma
Ovarian clear cell carcinoma (OCCC) is one of the rare subtypes of ovarian cancer, yet its prognosis is extremely poor. Previous studies indicate that both bevacizumab and PD-1 inhibitor have clinical benefits for OCCC patients. And the combination of bevacizumab and PD-1 inhibitor has shown preliminary safety and clinical activity. Therefore, this study aims to investigate the potential benefit of combination therapy for patients with OCCC.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
| Recruiting |
NCT05296512 -
Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT01914510 -
A Study of ENMD-2076 in Ovarian Clear Cell Cancers
|
Phase 2 | |
| Recruiting |
NCT04104776 -
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
|
Phase 1/Phase 2 | |
| Completed |
NCT03297424 -
A Study of PLX2853 in Advanced Malignancies.
|
Phase 1 | |
| Recruiting |
NCT03405454 -
A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas
|
Phase 2 | |
| Not yet recruiting |
NCT05600998 -
A Study of Camrelizumab in Combination With Anlotinib in Subjects Advanced Ovarian Clear Cell Carcinoma
|
N/A | |
| Recruiting |
NCT06065462 -
Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05099978 -
Asian Multicenter Prospective Study of ctDNA Sequencing
|
||
| Not yet recruiting |
NCT05759312 -
Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell Carcinoma
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06279104 -
A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary
|
||
| Terminated |
NCT02837991 -
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma
|
Phase 1 | |
| Recruiting |
NCT05498597 -
AMT-151 in Patients With Selected Advanced Solid Tumours
|
Phase 1 | |
| Recruiting |
NCT05226507 -
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
|
Phase 1 | |
| Recruiting |
NCT05281471 -
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Platinum-doublet + Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (OnPrime, GOG-3076)
|
Phase 3 | |
| Recruiting |
NCT02866370 -
Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium
|
Phase 2 |